Incyte to Report Third Quarter Financial Results
10/13/2021 - 08:00 AM
WILMINGTON, Del. --(BUSINESS WIRE)--
Incyte (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, November 2, 2021 .
The schedule for the press release and conference call/webcast is as follows:
• Q3 2021 Press Release:
November 2, 2021 at 7:00 a.m. ET
• Q3 2021 Conference Call:
November 2, 2021 at 8:00 a.m. ET
• Domestic Dial-In Number:
877-407-3042
• International Dial-In Number:
201-389-0864
• Conference ID Number:
13724199
If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay you will need the conference ID number 13724199.
The live webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for 90 days.
About Incyte
Incyte is a Wilmington, Delaware -based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte , please visit Incyte.com and follow @Incyte .
View source version on businesswire.com : https://www.businesswire.com/news/home/20211013005111/en/
Incyte Contacts
Media
Catalina Loveman
cloveman@incyte.com
Investors
Christine Chiou
cchiou@incyte.com
Source: Incyte
INCY Rankings
#3820 Ranked by Stock Gains
INCY Stock Data
Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
Sector
Professional, Scientific, and Technical Services
Tags
Health Technology, Biotechnology
Country
US
City
Wilmington
About INCY
incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. we have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. the incyte corporate headquarters is located in wilmington, delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders. for more information about incyte, please visit our corporate website at www.incyte.com.
